Clinical Research Details

Clinical Research

Gilead GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/ Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children

Study Description

To test the safety, effectiveness, and pharmacokinetics of a new HIV medication, GS-9883.

Participants will receive the new medication for 48 weeks. During that time, participants will have clinic visits, physical exams, and blood tests at Screening, Day 1, Weeks 1, 2, 4, 8, 12, 16, 24, 36, 48, and a 30 day follow-up visit.

Open Enrollment

Contact Name: Saniyyah Mahmoudi
Contact Phone: (904) 244-5331
Contact Email:


Sub Investigator
Nizar F. Maraqa, M.D.

Sub Investigator
Ayesha Mirza, M.D.